False-Positive FAPI Expression in Benign Breast Adenosis.

Breast adenosis is a benign glandular proliferative disorder. Due to its imaging similarities with other malignant breast lesions, differentiating adenosis from other invasive carcinomas of the breast poses a diagnostic challenge. Fibroblast activation protein inhibitor (FAPI) expression is observed in various benign and malignant lesions, increasing the risk of false-positive results.

Exploring the Role of [Ga]Ga-DOTAGA-IAC and Comparison of Its Diagnostic Performance with [F]F-FDG PET/CT in Radioiodine Refractory Differentiated Thyroid Carcinoma.

Integrin antagonist complex (IAC), a novel αvβ3 integrin antagonist peptidomimetic, has emerged as a promising agent for molecular imaging of tumor angiogenesis. This study evaluates the biodistribution and clinical efficacy of [Ga]Ga-DOTAGA-IAC PET/CT in detecting radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), comparing its diagnostic performance with [F]F-FDG PET/CT. In this prospective pilot study, RAIR-DTC patients underwent whole-body imaging with [F] F-FDG PET/CT, followed by [Ga]Ga-DOTAGA-IAC PET/CT.

Evaluation of Gluma® and MI Varnish™ for In-Office Treatment of Dentinal Hypersensitivity: An Observational Study.

Introduction In their routine practice, dentists frequently encounter dentinal hypersensitivity, which is caused by the pulpal nerves' increased excitability due to fluid movement in the dentinal tubules. It is treated in-office using dentin desensitizers, which reduce hypersensitivity by obstructing the open tubules or desensitizing the free nerve endings present within the tubules. However, no substance or treatment plan has ever been proven to be the gold standard for the efficient treatment of dentinal hypersensitivity.

Capsaicin content in chillies ( L., s L., Jacq.) of Northeast India by high performance thin layer chromatography (HPTLC).

Capsaicin is the primary bioactive constituent in chillies, responsible for its incomparable pungent taste and many health advantages. In the current study, 32 samples of three different species of ( L., s L.

Lu-DOTATATE Plus Capecitabine Versus Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial.

Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.